Actively Recruiting
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Led by Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Updated on 2026-04-06
398
Participants Needed
1
Research Sites
139 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main objective of this study is to evaluate the efficacy of SHR-A2102 versus investigator's choice of chemotherapy in patients with platinum-based chemotherapy and PD-(L)1 inhibitor treatment failed recurrent or metastatic cervical cancer.
CONDITIONS
Official Title
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Willing to participate and provide informed consent
- Histologically or cytologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma
- Cancer unsuitable for radical surgery and/or radical radiotherapy or chemoradiotherapy
- Provide primary or metastatic tumor samples
- Have at least one measurable lesion by RECIST version 1.1
- ECOG performance status 0 to 1
- Adequate organ function
- Expected overall survival of at least 12 weeks
You will not qualify if you...
- Known untreated or active central nervous system tumor metastasis or leptomeningeal metastasis
- Symptomatic or poorly controlled moderate-to-severe pleural effusion, pericardial effusion, or ascites
- History of or concurrent other malignant tumors
- Gastrointestinal or urogenital fistula or risk of fistula within 3 months prior to randomization
- Known or suspected interstitial lung disease
- Intestinal obstruction or signs/symptoms of obstruction within 3 months prior to randomization
- Poorly controlled cardiac symptoms or diseases
- Arterial or venous thromboembolic events within 3 months prior to randomization
- Severe infections within 1 month prior to randomization
- Active hepatitis B or C infection at screening
- Active tuberculosis infection within 1 year prior or history without proper treatment
- History of immunodeficiency or organ transplantation
- Systemic anti-tumor therapy within 28 days prior to randomization
- Uncontrolled psychiatric disorders or conditions affecting study completion
- Any condition increasing risk or interfering with study participation as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
Z
Zhifei Lin
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here